BIOCOM for BIOCOM
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for public health considerations in federal privacy legislation Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated against reasonable pricing provisions in NIH awards contracts Hosted a meeting with ARPA-H Director Wegrzyn on access to ARPA-H funding Hosted a meeting with FDA Tanya Clayton on the FDAs CMC pilot Hosted a meeting with BARDA on the DRIVE initiative
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| RICHARD WHITE | — |
Copyright/Patent/Trademark CPT
Advocated for the protection of Intellectual Property rights Advocated for the protection of the Bayh-Dole Act and against using march-in provisions to control drug pricing Expressed opposition to the proposals waiving IP protections for covid-19 vaccines, diagnostics, and treatments under the TRIPS agreement. Expressed opposition to FDA and PTO collaboration activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities Advocated in support of less restrictive merger & acquisition policies in life sciences
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| RICHARD WHITE | — |
Taxation/Internal Revenue Code TAX
Advocated to reverse a tax provision preventing businesses from deducting their R&D expenses in the same year they were incurred
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| RICHARD WHITE | — |
Trade (domestic/foreign) TRD
Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| RICHARD WHITE | — |
Budget/Appropriations BUD
Advocated for increased discretionary funding for HHS appropriations, including NIH, NCATS, CDC, BARDA, SNS Advocated for increased discretionary funding for FDA appropriations Advocated for increased discretionary funding for the VA appropriations, including the National Pharmacogenomic Program Advocated for increased discretionary funding for all federally funded scientific research institutions
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| RICHARD WHITE | — |
Agriculture AGR
Advocated for the expansion of the biopreferred program Advocated for the reauthorization of the Farm bill
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| RICHARD WHITE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.